CD274 and neoplasm: We next considered immuno-oncology biomarkers, including TMB (≥10 mutations/MB), PD-L1 (measured by IHC using the SP142 antibody with a positive threshold of ≥2+ intensity on ≥5% of tumor cells), and dMMR/MSI-High (measured by IHC and NGS, respectively).